Evista (raloxifene) affects the cycle of bone formation and breakdown in the body, and reduces loss of bone tissue.
Evista (raloxifine) is also used to treat and/or prevent osteoporosis in postmenopausal women. It is also used to reduce the risk of invasive breast cancer in postmenopausal women who have osteoporosis or who are otherwise at risk of invasive breast cancer.
Evista is not a cancer medication and will not treat breast cancer. Please consult your physician for proper management of other related symptoms that may persist during the medication
Taking Evista (raloxifine) may increase your risk of a blood clot which are located in the leg, lung, or eye. It should not take this medicine if you have ever had a blood clot.
Evista can also increase your risk of a stroke, which can be fatal. This risk is highest if you have coronary heart disease or certain risk factors (such as menopause, diabetes, smoking, being overweight, having high blood pressure or high cholesterol, having a family history of coronary artery disease, or if you have had a hysterectomy). Please consult your physician for proper management of other related symptoms other than indicated by the drug.
Stop taking raloxifene and get emergency help immediately if any of the following effects occur:
headache or migraine headache
loss of or change in speech, coordination, or vision
pain or numbness in chest, arm, or leg
shortness of breath (unexplained)
If any of the following side effects occur while taking raloxifene, check with your doctor or nurse as soon as possible:
Bloody or cloudy urine
difficult, burning, or painful urination
frequent urge to urinate
infection, including body aches or pain, congestion in throat, cough, dryness or soreness of throat, runny nose, and loss of voice
swelling of hands, ankles, or feet
The recommended dosage is one 60 mg EVISTA (raloxifene hydrochloride tablets) tablet daily, which may be administered any time of day without regard to meals